Compare Top Brokerages Here. Fate Therapeutics, Inc engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Shares of Fate Therapeutics were up more than 21% in premarket trading after the company announced a multi-billion dollar deal with Janssen Biotech to develop cell therapies for the treatment of cancer. It does make sense given oncology is a high value market and a single drug approval in this space would mean a significant growth in the companys sales from the $20 million currently. However, looking at the P/S for Fate is not helpful given the company doesnt have any marketable product yet, and it is more of a story of exciting products in the pipeline. While the usual process is to create a different batch for each patient from their own stem cells, Fate is intending for mass production of such treatment. The rise can largely be attributed to increased investor expectations from Fates pipeline, which focuses on a class of treatment that is based on Natural Killer cells. The stock price of Fate Therapeutics has seen a solid 16% rise over the last five trading days, while its up 13% over the last ten trading days, and we believe the rally may continue in the near term. Jeereddi Investments LP Increases Position in Alphabet Inc. Boothbay Fund Management LLC Buys Shares of 4,680 Sonoco Products. You can test the answer and many other combinations on the Trefis Machine Learning Engine to test Fate Therapeutics stock chances of a rise after a fall. However, the company saw a 62% growth in total shares outstanding due to share issuances, resulting in only a 61% growth in revenue per share to $0.16 in 2019, compared to $0.10 in 2017. Fate Therapeutics (NASDAQ:FATE Get Rating) was upgraded by equities researchers at StockNews.com from a sell rating to a hold rating in a research note issued on Thursday. The official website for the company is www.fatetherapeutics.com. Try the Trefis machine learning engine above to see for yourself how Fate Therapeutics stock is likely to behave after any specific gain or loss over a period. Insiders own 17.34% of the companys stock. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Going by the consensus revenue estimate of $20.4 million in 2020, FATE stock is trading at 456x its RPS of $0.25, which appears to be very high. Dive Brief: Johnson & Johnson will pay Fate Therapeutics $100 million to co-develop a group of allogeneic, or "off-the-shelf" cell therapies for cancer. Fate is in the mix, too, though it acknowledged COVID-19 could impact its plans. During the same quarter in the prior year, the firm posted ($0.72) EPS. Truist Financial reiterated a hold rating and issued a $7.00 target price (down from $46.00) on shares of Fate Therapeutics in a research note on Friday, January 6th. Given that the company does not have any marketable products currently, it generates revenues primarily from collaboration with other pharmaceutical companies. Her focus as a portfolio manager is solely on publicly traded companies with new cutting-edge technology and business models that have the edge over the competitors in their market. Young wrote the deal is also "a strong validation" of Fate's approach, which draws from stem cell and CAR-T technologies. Vertex Pharmaceuticals has signed a definitive agreement to acquire all outstanding shares of gene editing therapies developer Exonics Therapeutics for an upfront payment of $245m. 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Looking at the recent rally, the 9% rise for FATE stock over the last five days compares with a 0.7% growth seen in the broader S&P 500 index. [] Given that the company does not have any marketable products currently, it generates revenues primarily from collaboration with other pharmaceutical companies. U.S. regulators rejected Elon Musks bid to test brain chips in humans, Cell and Gene Therapy Manufacturing: Current and Future States, Proven Tips for Converting Sites to Single IRB, GSKs RSV vaccine wins FDA panel backing, matching Pfizer, FDA asks advisers to review Lynparza amid growing scrutiny of PARP drugs. Fate Therapeutics, Inc. (NASDAQ:FATE) issued its quarterly earnings results on Tuesday, February, 28th. contact@marketbeat.com How to Decide, Taiwan Semiconductor Manufacturing Expanding in the West, MarketBeat.com's FREE daily email newsletter. J&J sues Amgen over plan to sell ulcerative colitis drug similar to Stelara. Their FATE share price forecasts range from $7.00 to $90.00. On corrections down, there will be some support from the lines at $63.99 and $66.95. Research & Science Based on 84 salaries Scientist 30 salaries Senior Research Associate 7 salaries View More Engineering Based on 11 salaries Manufacturing Associate II Powered by Madgex Job Board Software. Adjusted EPS was $2.04 - up 92% year-on-year - and H1'22 EPS was reported. Fate Therapeutics' stock is owned by a variety of institutional and retail investors. With the shares down 60% following Fate's announced pipeline prioritization and Janssen termination, the "damage has largely been done and there is an opportunity for value-based, longer-term investors to step in," Nochomovitz tells investors in a research note. What happened When Celgene announced it was acquiring Juno. The securities described above are being offered by Fate Therapeutics pursuant to an automatic shelf registration statement on Form S-3 (File No. That said, the treatment is still in the very early stages of clinical trials, implying there is still some time before the drug can even move to late stage trials, let alone file for approval subject to a positive outcome of the upcoming studies. The companys approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Specifically, ARK Genomic Revolution ETF ( NYSEARCA: ARKG) bought 55,163 shares of Fate Therapeutics, and ARK Innovation ETF ( NYSEARCA: ARKK) bought 186,114 shares. C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121: Dulac Edward J Iii: officer: Chief Financial Officer: FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT STE 200, SAN DIEGO CA 92121: Yuan Xu: director: C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080: Robert S . While we believe that FATE stock is richly valued, the market potential is huge, especially in multi-billion dollar - oncology treatments. Fate turns cells from donors into induced pluripotent stem cells, which in turn can be re-engineered into a variety of different cells. It has seen positive findings from early trials for FT500, preventing disease progression for 11 out of 15 patients, something that has kept the stock price buzzing of late. Fate Therapeutics' stock was trading at $10.09 at the beginning of the year. CI Investments Inc. boosted its stake in shares of Fate Therapeutics by 413.7% during the 4th quarter. Following the completion of the transaction, the chief executive officer now owns 385,639 shares of the companys stock, valued at approximately $2,020,748.36. Fate Therapeutics does not have a long track record of dividend growth. | March 3, 2023 Quantbot Technologies LP bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $69,000. Some Fun Scenarios, FAQs & Making Sense of Fate Therapeutics Stock Movements: Question 1: Is the average return for Fate Therapeutics stock higher after a drop? Lazard Asset Management LLC owned approximately 0.17% of Fate Therapeutics worth $3,616,000 at the end of the most recent quarter. Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), CRISPR Therapeutics (CRSP), Juno Therapeutics (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD). The average twelve-month price prediction for Fate Therapeutics is $24.69 with a high price target of $90.00 and a low price target of $7.00. The biotech Nektar Therapeutics said late Monday that it would cut 70% of its workforce in an effort to extend its cash runway after the failure of its cancer drug partnership with Bristol Myers. [Updated: 2/10/2021] Can The FATE Stock Rally Continue?
While FATE stock may be overvalued, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. Several other hedge funds have also made changes to their positions in FATE. FT576. Fate is working toward a class of treatment that is based on NK cells. Fate is one of a group of companies advancing an "off-the-shelf" cell therapy approach, which utilizes cells taken from healthy donors. WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ: FATE) between April 2, 2020 and January 5, 2023, both dates inclusive (the "Class Period"). Insiders have sold a total of 75,708 shares of company stock worth $396,710 in the last ninety days. Some Fun Scenarios, FAQs & Making Sense of Fate Therapeutics Stock Movements:uestion 1: Is the average return for Fate Therapeutics stock higher after a drop? What is a Good Dividend Yield? Research & Development expenses surged to $44.8 million from $29.3 million in the year-ago quarter. Here's what Wall Street expects from Fate Therapeutics's earnings report, Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates, Fate Therapeutics GAAP EPS of -$0.58 beats by $0.29, revenue of $44.34M beats by $25.93M, FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus, Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) Price Target at $26.14, NK Cell Therapy Market 2023 to 2026 CONSUMER INSIGHTS with Dynamics Scenario, Induced Pluripotent Stem Cells (iPSCs) Market Size, Share & Trends Analysis Forecast Report by 2028, Fate Therapeutics (NASDAQ:FATE) Stock Price Down 7%, Natural Killer Cell Therapy Market Size 2023 NEWEST INDUSTRY DATA with Recent Industry Developments till 2028, Natural Killer Cell Therapy Market (New Insights Report) By 2023 which is Booming Strong Growth in the Globe till 2028, FATE Investors Have Opportunity to Lead Fate Therapeutics, Inc. Securities Fraud Lawsuit, Fate Therapeutics, Inc. (FATE) Class Action: Contact Robbins LLP for Information Regarding the Class Action and Lead Plaintiff Deadline, Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session, Needham Reaffirms Their Buy Rating on G1 Therapeutics (GTHX), Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results, ALERT: Investors in Fate Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FATE, CLASS ACTION UPDATE for AVYA, FATE and PHI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders, CLASS ACTION UPDATE for ENVX, YMAB and FATE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders, view top-rated stocks among Wall Street analysts, 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. See our analysis on Fate Therapeutics Stock Chances of Rise for more details. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $599.76 million and generates $96.30 million in revenue each year. Market Volatility To Continue Its The Economy (Stupid)! It didn't provide specific details. However, looking at the P/S for Fate is not helpful given the company doesnt have any marketable product yet, and it is more of a story of exciting products in the pipeline. At Tuesday's closing price,. Opinions expressed by Forbes Contributors are their own. Lazard Asset Management LLC Raises Stake in CDW Co. (NASDAQ:CDW), Verition Fund Management LLC Raises Stock Position in Teradyne, Inc. (NASDAQ:TER), Get a free copy of the StockNews.com research report on Fate Therapeutics (FATE). FATE - Fate Therapeutics, Inc. Stock Price and Quote TIP: Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools. Kessler Investment Group LLC bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $82,000. See Top Rated MarketRank Stocks Here To The Moon: Intuitive Machines Blasts 10x in a WeekBut Why? She looks for companies that are changing the . Israel had more companies listed in 2012 on the NASDAQ stock exchange than any country outside the United States, save China. According to analysts' consensus price target of $24.69, Fate Therapeutics has a forecasted upside of 305.4% from its current price of $6.09.